Mohamed S Abdelbaki1, Mohammad H Abu-Arja2, Tom B Davidson3, Jason R Fangusaro4, Joseph R Stanek1, Ira J Dunkel5, Girish Dhall6, Sharon L Gardner7, Jonathan L Finlay1. 1. The Division of Hematology, Oncology and Blood and Marrow Transplant, Nationwide Children's Hospital and The Ohio State University, Columbus, Ohio. 2. The Department of Pediatrics, New York-Presbyterian Brooklyn Methodist Hospital, Weill-Cornell College of Medicine, Brooklyn, New York. 3. The Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California. 4. The Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, Georgia. 5. The Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York. 6. The Division of Pediatric Hematology, Oncology and Bone Marrow Transplantation at the University of Alabama at Birmingham, Birmingham, Alabama. 7. The Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, New York University, New York City, New York.
Abstract
BACKGROUND: We report the outcomes of patients with pineoblastoma and trilateral retinoblastoma syndrome enrolled on the Head Start (HS) I-III trials. METHODS: Twenty-three children were enrolled prospectively between 1991 and 2009. Treatment included maximal surgical resection followed by five cycles of intensive chemotherapy and consolidation with marrow-ablative chemotherapy and autologous hematopoietic cell rescue (HDCx/AuHCR). Irradiation following consolidation was reserved for children over six years of age or those with residual tumor at the end of induction. RESULTS: Median age was 3.12 years (range, 0.44-5.72). Three patients withdrew from the study treatment and two patients experienced chemotherapy-related death. Eight patients experienced progressive disease (PD) during induction chemotherapy and did not proceed to HDCx/AuHCR. Ten patients received HDCx/AuHCR; eight experienced PD post-consolidation. Seven patients received craniospinal irradiation (CSI) with a median dose of 20.7 Gy (range, 18-36 Gy) with boost(s) (median dose 27 Gy; range, 18-36 Gy); three received CSI as adjuvant therapy (two post-HDCx/AuHCR) and four upon progression/recurrence. The five-year progression-free survival (PFS) and overall survival (OS) were 9.7% (95% confidence intervals [CI]: 2.6%-36.0%) and 13% (95% CI: 4.5%-37.5%), respectively. Only three patients survived beyond five years. Favorable OS prognostic factors were CSI (hazard ratio [HR] = 0.30 [0.11-0.86], P = 0.025) and HDCx/AuHCR (HR = 0.40 [0.16-0.99], P = 0.047). CONCLUSIONS: Within the HS I-III trials, CSI and HDCx/AuHCR were statistically associated with improved survival. The high PD rate during later induction cycles and following consolidation chemotherapy warrants consideration of fewer induction cycles prior to consolidation and the potential intensification of consolidation with multiple cycles of marrow-ablative chemotherapy and irradiation.
BACKGROUND: We report the outcomes of patients with pineoblastoma and trilateral retinoblastoma syndrome enrolled on the Head Start (HS) I-III trials. METHODS: Twenty-three children were enrolled prospectively between 1991 and 2009. Treatment included maximal surgical resection followed by five cycles of intensive chemotherapy and consolidation with marrow-ablative chemotherapy and autologous hematopoietic cell rescue (HDCx/AuHCR). Irradiation following consolidation was reserved for children over six years of age or those with residual tumor at the end of induction. RESULTS: Median age was 3.12 years (range, 0.44-5.72). Three patients withdrew from the study treatment and two patients experienced chemotherapy-related death. Eight patients experienced progressive disease (PD) during induction chemotherapy and did not proceed to HDCx/AuHCR. Ten patients received HDCx/AuHCR; eight experienced PD post-consolidation. Seven patients received craniospinal irradiation (CSI) with a median dose of 20.7 Gy (range, 18-36 Gy) with boost(s) (median dose 27 Gy; range, 18-36 Gy); three received CSI as adjuvant therapy (two post-HDCx/AuHCR) and four upon progression/recurrence. The five-year progression-free survival (PFS) and overall survival (OS) were 9.7% (95% confidence intervals [CI]: 2.6%-36.0%) and 13% (95% CI: 4.5%-37.5%), respectively. Only three patients survived beyond five years. Favorable OS prognostic factors were CSI (hazard ratio [HR] = 0.30 [0.11-0.86], P = 0.025) and HDCx/AuHCR (HR = 0.40 [0.16-0.99], P = 0.047). CONCLUSIONS: Within the HS I-III trials, CSI and HDCx/AuHCR were statistically associated with improved survival. The high PD rate during later induction cycles and following consolidation chemotherapy warrants consideration of fewer induction cycles prior to consolidation and the potential intensification of consolidation with multiple cycles of marrow-ablative chemotherapy and irradiation.
Authors: Panagiotis Kerezoudis; Yagiz Ugur Yolcu; Nadia N Laack; Michael W Ruff; Soumen Khatua; David J Daniels; Terry C Burns; Sani H Kizilbash Journal: Neurooncol Adv Date: 2022-04-17
Authors: Anthony P Y Liu; Bryan K Li; Elke Pfaff; Brian Gudenas; Alexandre Vasiljevic; Brent A Orr; Christelle Dufour; Matija Snuderl; Matthias A Karajannis; Marc K Rosenblum; Eugene I Hwang; Ho-Keung Ng; Jordan R Hansford; Alexandru Szathmari; Cécile Faure-Conter; Thomas E Merchant; Max Levine; Nancy Bouvier; Katja von Hoff; Martin Mynarek; Stefan Rutkowski; Felix Sahm; Marcel Kool; Cynthia Hawkins; Arzu Onar-Thomas; Giles W Robinson; Amar Gajjar; Stefan M Pfister; Eric Bouffet; Paul A Northcott; David T W Jones; Annie Huang Journal: Acta Neuropathol Date: 2021-02-22 Impact factor: 15.887
Authors: Marcus C de Jong; Furqan Shaikh; Brenda Gallie; Wijnanda A Kors; Robin W Jansen; Charlotte Dommering; Pim de Graaf; Annette C Moll; Helen Dimaras; Manohar Shroff; Tero T Kivelä; Sameh E Soliman Journal: Acta Ophthalmol Date: 2021-05-03 Impact factor: 3.988